Avacta Share Discussion Threads

[bbd2] 10/10/2024 10:18

Nice. HP sauce with the crispy bacon anyone? Some worried shorter out there.

[viking24] 10/10/2024 08:43

Look out for test trades at offer, before size moves in.

[quazie12] 10/10/2024 08:28

Sell up and jog on then. Give us peace ffs

[baldrick1] 10/10/2024 08:14

Inject more shorts for the incinerator;)))

[1347] 10/10/2024 08:13

This looks to me like typical Avacta, they have to find new rainbows to cover up for the fact that the old ones disappeared like scotch mist on a sunny day. As well as the longest running Phase 1 trial I've ever known, what the hell happened to their second candidate AVA3996, it was supposed to be in Phase 1 a year ago?

18 January 2022

"Avacta Selects Second pre|CISIONTM Pro-drug Candidate for Development
Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms announces that the next pre|CISIONTM drug candidate, AVA3996, has been selected for pre-clinical development with a view to a first-in-human Phase I clinical trial beginning in the second half of 2023."

[pwhite73] 10/10/2024 08:04

The most important thing is that both Generation Two and Generation Three are both at the preclinical stage so Avacta does not have to worry about silly subjects like efficacy for the next two to three years.

[pwhite73] 10/10/2024 07:52

RNS 10/10/24 - "The second advance in the pre|CISION™ platform is the first description of a novel class of engineered biotherapeutics, called Affirmer® Drug Conjugates"

This is a lie because they have been working on Affirmer® Drug Conjugates since 2019 exactly five years to the day.

RNS 10/10/2019 - "Focus on developing potent Affimer-drug conjugates"

[repins1] 10/10/2024 07:33

A very misleading rns that it's either a breakthrough or it isn't, or in this case a potential breakthrough, if this statement was elsewhere in the cancer world it would get shafted

[viking24] 10/10/2024 07:15

DCX disposal next headline

[bittorrent] 10/10/2024 07:14

Maybe I'm being pedantic but I wish they would make their minds up, is it Affimer or Affirmer?

[baldrick1] 10/10/2024 07:09

More regular news and more regular shorts are scorched ;)))

[blackhorse23] 10/10/2024 06:51

Every year is a placing year lol

[blackhorse23] 10/10/2024 06:51

Probably needs another placing , so it is making new stories. Doing research last 10 years and no outcome , results are 0 , I don't see any future for this company

[hamidahamida] 10/10/2024 06:50

Years away from making any money IF all goes well BUTOne thing is for sure like Every placing in the past, the ones in future will be lower price then the preceding one Death by Deeply Discounted Dilution

[repins1] 10/10/2024 06:42

Potentially and breakthrough words should never be used together

[robers98] 10/10/2024 06:30

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted cancer treatments, today announced that the Company will present new preclinical data on two breakthroughs in the pre|CISION™ platform in poster sessions at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain from 23-25 October 2024. Together, the presentations advance the utility of our pre|CISION™ drug delivery platform technology, which delivers highly potent warheads directly to the tumor microenvironment while minimizing exposure in normal tissues, thus allowing dosing to be optimized to deliver the best outcomes for patients.

The first advance in the pre|CISION™ platform is the design and preclinical analysis of the Company’s newest development candidate, AVA6103, a novel, potent peptide drug conjugate (PDC) that FAP-enables the most potent Topoisomerase I inhibitor in clinical testing, via the pre|CISION™ technology with tumor-specific delivery of the warhead to induce DNA damage and drive cancer cell death. AVA6103 is a Generation Two pre|CISION™ PDC in the Avacta pipeline.

The second advance in the pre|CISION™ platform is the first description of a novel class of engineered biotherapeutics, called Affirmer® Drug Conjugates, that are dual-targeting and have the potential to offer a delivery mechanism with greater specificity than the PDC, thus potentially unlocking the patient populations with low expression of FAP in the tumor. This program is a Generation Three pre|CISION™ medicine and utilizes the same release mechanism in the pre|CISION™ platform. Based on this, the Affimer drug conjugates have the potential to not only increase the specificity of delivery but to also minimize systemic exposure to the warhead.

[amanitaangelicus] 09/10/2024 08:33

Yes, plenty of competitors for sure. Fingers, toes crossed. We need mega tech shifts for C treatments. Bldy awful thing

[amanitaangelicus] 09/10/2024 08:22

Yes, plenty of competitors for sure. Fingers, toes crossed. We need mega tech shifts for C treatments. Bldy awful thing

[baldrick1] 09/10/2024 07:58

Still many investors are putting their money here for the good of humanity.

[amanitaangelicus] 08/10/2024 15:02

Transfer of shares from the rich to the not so s. Rinse repeat.

[g2theary] 08/10/2024 14:15

Shorts closing here if someone started buying this. Would race ;)

[1347] 08/10/2024 10:36

You can argue all you like about DBs analysis and share price target but the facts remain.

The Phase 1a trial has taken over 3 years and counting, this for a drug candidate that's been around for over 10 years (with Arisaph initially) delivering Dox differently, Dox has been around even longer.

Thus far there has been no quantifiable and demonstrable data on efficacy, just observations, and I don't see how you can establish cause and effect from what they've published so far.

As far as I know they haven't yet got approval for a Phase II trial, dates are slipping on that already aren't they?

Avacta have a track record of promoting discoveries that will be ground breaking only to fall flat on their face. The Affimer tests were the acid test (if you'll forgive the pun), the best in the world they said, we'll sell all we can make they said, yet nowhere to be seen now.

Death spiral finance is running with over £30m still to pay. The lower the share price the more dilution it will cause.

You can place your trust in what the latest BoD say, having had to essentially replace the last one, but I'll not be doing that again after the LFT fiasco. I need peer reviewed efficacy data and that's light years away at the current crawl.